Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TARS
TARSUS PHARMACEUTICALS, INC.
NASDAQ
$71.76
▼ DOWN 0.22% (-0.16)

KEY STATISTICS

Market Cap$3.09 B
52w High$85.25
52w Low$48.20
Dividend Yield—
Frequency—
P/E-65.83
Volume615.72K
Shares Out.43.02M

COMPANY

LEADERSHIP

Bobak R. Azamian
CHIEF EXECUTIVE
Bobak R. Azamian

COMPENSATION 2026

Salary$726,333
Stock Awards$2,648,284
Incentive Plan Pay$555,700
All Other Comp.$36,175
Total$6,617,979

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 16, 2020
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
370

PRICE TARGET

Target High$100.00
Target Low$89.00
Target Median$98.00
Target Consensus$95.67

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$183.57M
NOV
3
TUE

PRICE

$71.76 ▼ DOWN 0.22% (−$0.16)
$70.80$71.20$71.60$72.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM71.76

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com ↗

Tarsus Pharmaceuticals, a clinical-stage biotech based in Irvine, develops novel ophthalmic and dermatologic therapies, including TP-03 for blepharitis, with additional candidates for rosacea, Lyme, malaria, and other diseases.

INDUSTRY

Biotechnology

A PRODUCT TARSUS PHARMACEUTICALS, INC. IS KNOWN FOR

XDEMVY™ (lotilaner ophthalmic solution) 0.25%
XDEMVY™ (lotilaner ophthalmic solution) 0.25%

XDEMVY™ is the first FDA-approved prescription eye drop that directly eradicates Demodex mites, offering a groundbreaking treatment for Demodex blepharitis, a common eyelid disease affecting millions.

COMPETITORS

COMPETITOR
ABBV COMPARE
ALC COMPARE
BLCO COMPARE
NVS COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$118.7M $151.67M ▲$145.39M ▼$173.91M ▲
License And Collaboration— — $16.67M —

ETFS HOLDING THIS STOCK

ETFS HOLDING
128
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.00% · 1.3M
IWM
0.09% · 1.1M
PJP
2.90% · 216.2K
SCHA
0.06% · 187.3K
XPH
1.67% · 136.1K
FTXH
0.41% · 60.6K
SBIO
1.57% · 52.9K
XRSG.L
0.09% · 37.5K
HAPS
1.19% · 29.3K
GSSC
0.17% · 25.9K
BBP
1.43% · 23.6K
RSSL
0.09% · 20.0K
FHLC
0.03% · 14.3K
BBSC
0.10% · 11.0K
PILL
1.12% · 3.8K
RTWO.L
0.12% · 3.8K
FSML
0.08% · 1.8K
URTY
0.04% · 1.7K
TILT
0.01% · 1.6K
STXK
0.12% · 1.4K
BKSE
0.12% · 1.4K
ESSC
0.16% · 952
RFLR
0.07% · 948
ACSG
0.11% · 802
USFMDN.MX
0.01% · 155
RESM
0.14% · 116

INSTITUTIONAL OWNERSHIP

SHARES OWNED
75.05%
HOLDERS
336
TOP 12 OF 336 · RANKED BY POSITION SIZE
Blackrock, Inc.
3.9M sh · $242.71M
Deep Track Capital, LP
3.7M sh · $230.79M
Rtw Investments, LP
3.4M sh · $211.29M
Blackrock Inc.
3.3M sh · $88.79M
Paradigm Biocapital Advisors LP
2.8M sh · $174.7M
Jennison Associates LLC
2.6M sh · $154.79M
Tang Capital Management LLC
2.5M sh · $145.89M
Vanguard Group Inc
2.4M sh · $196.48M
Janus Henderson Group Plc
2.2M sh · $157.22M
Cowen And Company, LLC
2.2M sh · $72.27M
Morgan Stanley
2.0M sh · $167.1M
Millennium Management LLC
1.4M sh · $89.82M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Goldberg Andrew D.
Purchase · 2.4K shares
2026-06-25
★
DIRECTOR
Morrison Scott W
Purchase · 3.8K shares
2026-06-25
★
DIRECTOR
CHAUDHURI BHASKAR
Purchase · 3.8K shares
2026-06-25
★
DIRECTOR
Goodrich Katherine
Purchase · 3.8K shares
2026-06-25

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
BUY 2
4 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM Mizuho OUTPERFORM Guggenheim BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
SRRK$57.80COMPARE
CGON$74.34COMPARE
TVTX$65.67COMPARE
CELC$88.44COMPARE
ADPT$25.19COMPARE
LEGN$19.88COMPARE
IRON$80.03COMPARE
ARQT$23.78COMPARE